Lipids and Diabetic Retinopathy

被引:33
作者
Modjtahedi, Bobeck S. [1 ]
Bose, Namrata [2 ]
Papakostas, Thanos D. [1 ]
Morse, Lawrence [3 ]
Vavvas, Demetrios G. [1 ]
Kishan, Amar U. [4 ]
机构
[1] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Boston, MA 02114 USA
[2] Univ So Calif, Keck Sch Med, Dept Endocrinol, Los Angeles, CA 90033 USA
[3] Univ Calif Davis, Sch Med, Dept Ophthalmol & Vis Sci, Davis, CA 95616 USA
[4] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
lipid metabolism; Diabetic retinopathy; statins; fibrates; lipoprotein; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; PIGMENT EPITHELIAL-CELLS; SEVERE VISUAL-LOSS; MACULAR EDEMA; SERUM-LIPIDS; PITTSBURGH EPIDEMIOLOGY; VITREOUS FLUID; OXIDIZED LDL; RISK-FACTORS;
D O I
10.3109/08820538.2015.1114869
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The relationship between lipids and the development and/or severity of diabetic retinopathy (DR) is complex. Large epidemiologic studies suggest an inconsistent and overall modest association between serum triglycerides or major cholesterol species and the severity of DR; however, certain specific lipoprotein species may have stronger associations with DR severity, suggesting a pathophysiological role for lipoproteins analogous to that seen in atherosclerosis. In this lipoprotein-mediated DR pathogenesis model, damage to the blood-retinal barrier allows extravasation of lipoprotein species, which are modified in the intraretinal environment, creating substantial local damage. Additionally, hypolipidemic therapy with statins and fibrates-particularly the latter-have been shown to modulate DR in large-scale studies. Since serum lipid profile changes do not necessarily correlate with DR modulation, the efficacy of these agents may be due to their tissue-specific changes in lipoproteins and/or their anti-inflammatory, antioxidative, antiangiogenic, and antiapoptotic functions.
引用
收藏
页码:10 / 18
页数:9
相关论文
共 101 条
  • [1] Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy
    Abu El-Asrar, Ahmed M.
    Nawaz, Mohd Imtiaz
    Mohammad, Ghulam
    Siddiquei, Mohammad Mairaj
    Alam, Kaiser
    Mousa, Ahmed
    Opdenakker, Ghislain
    [J]. LIPIDS IN HEALTH AND DISEASE, 2014, 13
  • [2] Diabetic retinopathy - Biomolecules and multiple pathophysiology
    Ahsan, Haseeb
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2015, 9 (01) : 51 - 54
  • [3] Role of NADPH oxidase and stat3 in statin-mediated protection against diabetic retinopathy
    Al-Shabrawey, Mohamed
    Bartoli, Manuela
    El-Remessy, Azza B.
    Ma, Guochuan
    Matragoon, Suraporn
    Lemtalsi, Tahira
    Caldwell, R. William
    Caldwell, Ruth B.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (07) : 3231 - 3238
  • [4] [Anonymous], 2013, J CLIN EXP OPHTHALMO
  • [5] Fibrates and Statins in the Treatment of Diabetic Retinopathy
    Ansquer, Jean-Claude
    Crimet, Dominique
    Foucher, Christelle
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (03) : 396 - 405
  • [6] Mechanisms of Disease Diabetic Retinopathy
    Antonetti, David A.
    Klein, Ronald
    Gardner, Thomas W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13) : 1227 - 1239
  • [7] Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
    Banerjee, S
    Denniston, AKO
    Gibson, JM
    Dodson, PM
    [J]. EYE, 2004, 18 (08) : 821 - 825
  • [8] Role of Cytosolic Phospholipase A2 in Retinal Neovascularization
    Barnett, Joshua M.
    McCollum, Gary W.
    Penn, John S.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (02) : 1136 - 1142
  • [9] PPARs and angiogenesis
    Bishop-Bailey, David
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2011, 39 : 1601 - 1605
  • [10] Examining the role of lipid mediators in diabetic retinopathy
    Busik, Julia V.
    Esselman, Walter J.
    Reid, Gavin E.
    [J]. CLINICAL LIPIDOLOGY, 2012, 7 (06) : 661 - 675